Skip to content

13F-HR filed by GREAT POINT PARTNERS LLC

GREAT POINT PARTNERS LLC filed this 13F-HR for the quarter ended 2018-09-30, filed 2018-11-14, with 30 holding rows worth $641,666,000.

Accession
0000930413-18-003323
Filed
2018-11-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2018

A holdings report, 30 entries on the cover page, a total value of $641,666,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $641,666,000 with VALUE read as thousands by filing date, 13F file number 028-11743. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
BIOCRYST PHARMACEUTICALS INC COM09058V103Stock7,978,275$60,874,000thousands by filing date
ACCELERON PHARMA INC00434H108COM917,767$52,524,000thousands by filing date
ZAFGEN INC98885E103COM3,391,385$39,645,000thousands by filing date
IOVANCE BIOTHERAPEUTICS INC462260100COM3,496,340$39,334,000thousands by filing date
UNITED THERAPEUTICS CORP DEL COM91307C102Stock300,000$38,364,000thousands by filing date
KURA ONCOLOGY INC COM50127T109Stock2,119,106$37,084,000thousands by filing date
EXELIXIS INC COM30161Q104Stock2,075,000$36,769,000thousands by filing date
PTC THERAPEUTICS INC69366J200COM717,458$33,721,000thousands by filing date
ENDOCYTE INC29269A102COM1,606,100$28,524,000thousands by filing date
VOYAGER THERAPEUTICS INC92915B106COMMON STOCK1,400,000$26,488,000thousands by filing date
ALNYLAM PHARMACEUTICALS INC COM02043Q107Stock300,000$26,256,000thousands by filing date
SAVARA INC805111101COM2,243,084$25,033,000thousands by filing date
ACADIA PHARMACEUTICALS INC004225108COM1,196,098$24,831,000thousands by filing date
FOAMIX PHARMACEUTICALS LTDM46135105SHS4,030,268$23,094,000thousands by filing date
FIVE PRIME THERAPEUTICS INC.33830X104Common Stock1,647,753$22,937,000thousands by filing date
CYTOKINETICS INC23282W605COM NEW2,179,688$21,470,000thousands by filing date
SPARK THERAPEUTICS INC84652J103COM393,147$21,446,000thousands by filing date
ENANTA PHARMACEUTICALS INC29251M106COM210,400$17,981,000thousands by filing date
MENLO THERAPEUTICS INC586858102COM1,304,407$12,848,000thousands by filing date
TG THERAPEUTICS INC COM88322Q108Stock1,950,000$10,920,000thousands by filing date
PROTAGONIST THERAPEUTICS74366E102COM982,449$10,109,000thousands by filing date
ARGENX SE SPONSORED ADR04016X101ADR129,060$9,788,000thousands by filing date
MADRIGAL PHARMACEUTICALS INC COM558868105Stock40,400$8,651,000thousands by filing date
INTRA-CELLULAR THERAPIES INC46116X101COMMON STOCK200,000$4,340,000thousands by filing dateput
ZYMEWORKS INC98985W102COM241,970$3,799,000thousands by filing date
SUNESIS PHARMACEUTICALS INC867328700COM1,000,000$2,000,000thousands by filing date
ACER THERAPEUTICS INC00444P108CMN58,461$1,803,000thousands by filing date
SIERRA ONCOLOGY INC82640U107COM490,843$834,000thousands by filing date
STREAMLINE HEALTH SOLUTIONS86323X106COM130,137$153,000thousands by filing date
CTI BIOPHARMA CORP12648L601COM21,441$46,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000930413-18-003323this filing2018-11-14acceptance time not in the bulk data set